MelliCell Secures SEED Grant to Advance Diabetes and Obesity Research

MelliCell Inc., a leading biotech company specializing in adipocyte therapies for chronic diseases, has been awarded a significant SEED grant from the NIH/NIDDK. In collaboration with Mass General Brigham, a top biomedical research organization, MelliCell aims to enhance treatments for diabetes and obesity. This grant falls under the Small Business Innovation Research Program, providing access to $1.2 billion for entrepreneurial development.

The company's innovative technology can generate mature human fat tissue, creating new possibilities for chronic disease therapies. The partnership with Mass General Brigham will enable research into how genetic mutations affect fat cells related to diabetes and obesity. MelliCell's research focus includes improving treatment tolerability and effectiveness.

This funding positions MelliCell to accelerate its R&D efforts, addressing major health challenges globally.